Biogen announces $5B stock buyback on heels of Alzheimer’s hit

For the second time in a year, Biogen has announced a share repurchase program on the heels of bad news from an Alzheimer's candidate. This time, the big biotech has authorized the repurchase of $5 billion in stock in addition to $1.7

Read the full 422 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE